Quantcast
Home > Quotes > BMY

Bristol-Myers Squibb Company Common Stock (BMY) Quote & Summary Data

BMY 
$53.93
*  
1.50
2.86%
Get BMY Alerts
*Delayed - data as of Dec. 12, 2018 10:26 ET  -  Find a broker to begin trading BMY now
Exchange:NYSE
Industry: Health Care
Community Rating:
View:    BMY Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

1 Year Target
60
Today's High / Low
$ 54.25 / $ 52.96
Share Volume
1,091,113
90 Day Avg. Daily Volume
7,461,315
Previous Close
$ 52.43
52 Week High / Low
$ 70.05 / $ 46.94
Market Cap
88,024,479,882
P/E Ratio
61.28
Forward P/E (1y)
13.55
Earnings Per Share (EPS)
$ 0.88
Annualized Dividend
$ 1.64
Ex Dividend Date
1/3/2019
Dividend Payment Date
2/1/2019
Current Yield
3.04 %
Beta
0.27

Intraday Chart

Shares Traded

Share Volume:
1,091,113
90 Day Avg. Daily Volume:
7,461,315

P/E Ratio

P/E Ratio:
61.28
Forward P/E (1y):
13.55
Earnings Per Share (EPS):
$ 0.88

Trading Range

The current last sale of $53.93 is 14.89% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 54.25 $ 70.05
 Low: $ 52.96 $ 46.94

ETFs with BMY as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
3.85% First Trust Nasdaq Pharmaceuticals ETF (FTXH) -1.14 (-5.18%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

Bristol-Myers Squibb Company was incorporated under the laws of the State of Delaware in August 1933 under the name Bristol-Myers Company, as successor to a New York business started in 1887. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger. We are engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Refer to the Summary of Abbreviated Terms at the end of this 2017 Form 10-K for terms used throughout the document. We operate in one segment--BioPharmaceuticals. For additional information about business segments, refer to "Item 8. Financial Statements--Note 2. Business Segment Information." We compete with other worldwide research-based drug companies, smaller research companies and generic drug manufacturers.  ... More ...  


Risk Grade

Where does BMY fit in the risk graph?


Risk Grade Scale

Consensus Recommendation

Analyst Info